← Back to Search

Other

CO2 Laser Therapy for Peyronie's Disease

N/A
Waitlist Available
Led By Ryan Flannigan, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change in penile measurements (baseline vs. week 18, 24, & 52).
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a laser therapy to treat men with Peyronie's Disease by breaking down scar tissue in the penis, aiming to improve its shape and function without invasive procedures. Laser therapy has been proposed with success in the treatment of Induratio Penis Plastica (IPP), also called Peyronie's Syndrome.

Who is the study for?
This trial is for healthy males aged 18 or older, diagnosed with Peyronie's Disease for at least a year and have stable disease. They must be in a stable relationship, able to read and understand English, and willing to sign consent forms. Men with penile curvature between 30º-90º are eligible.
What is being tested?
The study tests Fractional Carbon Dioxide Laser Therapy as a treatment for Peyronie's Disease. Participants will receive this therapy at a laser density coverage of 10-15%. It's designed to see if the laser can help reduce symptoms of the disease.
What are the potential side effects?
Potential side effects may include discomfort during the procedure, redness, swelling, burning sensation on treated areas, changes in skin pigmentation, and scarring.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change in penile measurements (baseline vs. week 18, 24, & 52).
This trial's timeline: 3 weeks for screening, Varies for treatment, and change in penile measurements (baseline vs. week 18, 24, & 52). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Measured reduction in penile curvature
Secondary study objectives
International Index of Erectile Function Questionnaire
Peyronie's Disease Questionnaire

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Fractional CO2 Laser Therapy at 10-15% Laser Density CoverageExperimental Treatment1 Intervention
Study participants with Peyronies Disease will be treated with a Fractional Carbon Dioxide Laser set at a 10-15% laser density. The patient will receive three laser therapy sessions over 12 weeks (one session every four weeks). Following each session, topical triamcinolone will be applied to the treated area.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage
2021
N/A
~10

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,485,451 Total Patients Enrolled
Ryan Flannigan, MDPrincipal InvestigatorUBC Faculty of Medicine - Department of Urologic Sciences
1 Previous Clinical Trials
12 Total Patients Enrolled

Media Library

Fractional Carbon Dioxide Laser Therapy (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04326465 — N/A
Peyronie's Disease Research Study Groups: Fractional CO2 Laser Therapy at 10-15% Laser Density Coverage
Peyronie's Disease Clinical Trial 2023: Fractional Carbon Dioxide Laser Therapy Highlights & Side Effects. Trial Name: NCT04326465 — N/A
Fractional Carbon Dioxide Laser Therapy (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04326465 — N/A
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top